<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040373</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cardiovascular risk in hemodialysis in spain: prevalence, management and target results (MAR study)</dc:title>
<dc:description xml:lang="en">Cardiovacular disease is the main cause of morbidity and mortality in hemodialysis(HD) patients. However, there are no reliable data neither on the prevalence of cardiovaculardisease nor its risk factors in Spain. The Morbidity and mortality AnemiaRenal study (MAR) is a two-year multicenter, open-label, prospective cohorts study. Itsmain objective is to assess the general morbidity and mortality, particularly of a cardiovascularcause, and its relationship with the degree of anemia. Secondary objectivesare: a/ the description of current clinical practices in anemia, dialysis, vascular access,and CV risk factor management; and b/ the description of hospitalization andmortality causes. This paper describes the prevalence of cardiovascular disease andrisk factors of the HD population in Spain. A total of 1.710 patients were included(60% male, aged 64.4 years, 16.2 months on HD). The mean co-morbidity Charlsonindex was 6.5 ± 2.3. Cardiovascular disease was the most prevalent comorbidity, 16.7%had a coronary disease, and 13.9% had different degrees of heart failure, while 11.6%had arrhythmia, 1.7% stroke and 5.5% peripheral artery disease. The prevalence ofhypertension was 75,8%, 74,4% of patients received antihypertensive drugs, and still40% of patiens had an inadequate blood pressure control. The investigators consideredas dyslipidemic 34.1% of patients, and prescribed treatment to 69.5% of them,while the remaining 30.5% (10.4% of the total) had hyperlipidemia with no drug therapy.Eleven percent was active smoker, and 26,6% former smoker. There was 47,4%of patients with a corporal mass index above 25. Secondary hyperparathyroidism withPTH above of 300 pg/ml was present in 22.2% of patients. Despite the EBPG andK-DOQI recommendations, only 68.8% of prevalent hemodialysis patients attained ahemoglobin (Hb) above 11 g/dl, 89.4% ferritin levels above 100 ng/ml, 66.5°/a atransferrin saturation index (TSI) above 20%, and 61.1% met all three objectives. Insummary, this first cross-sectional analysis has allowed us to know in detail the standardpractice in multiple aspects of management of HD population in Spain. It hasalso established clear differences in the prevalence of cardiovascular disease and riskfactors from the US registries. Last but not least we have identified therapeutic opportunitiesto improve the course and prognosis of our patients</dc:description>
<dc:creator>Aljama, P</dc:creator>
<dc:creator>López-Gómez, JM</dc:creator>
<dc:creator>Portolés, J</dc:creator>
<dc:creator>Tato, AM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad cardiovascular (CV) es la principal causa de morbi-mortalidaden enfermos en hemodiálisis (HD). Sin embargo no disponemos actualmente dedatos sobre la prevalencia de sus diferentes manifestaciones, ni de sus factores deriesgo en la población en HD española. Morbidity and mortality Anemia Renalstudy (MAR) es un estudio descriptivo, prospectivo, multicéntrico y abierto deserie de casos. Su objetivo principal es la valoración de la morbilidad y mortalidadgeneral, especialmente de causa CV, y su relación con el grado de anemia.Los objetivos secundarios son la descripción de las pautas habituales de manejode estos pacientes y los objetivos de control alcanzados. Presentamos aquí el análisisdescriptivo del riesgo CV en la población del estudio MAR. Se incluyeron1.710 enfermos prevalentes de 119 centros (60% varones, 64,4 años, tiempo enHD 15,9 meses). La prevalencia de diabetes (DM) tipo 1 era del 4,3% y de DMtipo II 21,6%. En el momento de la inclusión el 16,7% presentaban enfermedadcoronaria, 13,9% insuficiencia cardíaca, 11,6% arritmias, 2,0% ACVA y 5,5% enfermedadarterial periférica. El índice de comorbilidad de Charlson era de 6,53 ±2,3. El 75,8% de pacientes eran hipertensos (74,4% en tratamiento farmacológico,40% mal controlado). El 34,1% presentaba dislipemia. Un 83,2% de los dislipémicosno tratados y un 52,7% de los considerados no dislipémicos cumplíancriterios para precisar tratamiento. El 11% era fumador y el 26,6% ex-fumadores.El 47,4% presentaba un peso superior al adecuado. El 22,2% de los enfermospresentaba PTH &gt; 300 pg/dl. El 68,8% tenía una hemoglobina &gt; 11 g/dl, un89,4% ferritina &gt; 100 ng/ml y un 66,5% un IST &gt; 20%. En resumen, estamosaún lejos de cumplir los objetivos de las guías de riesgo CV, pero conocemos conmás precisión estos parámetros y hemos identificado oportunidades terapéuticaspara mejorar la evolución y el pronóstico de nuestros pacientes</dc:description>
<dc:source>Nefrologia;25(3): 297-306, mayo 2005. tab</dc:source>
<dc:identifier>ibc-040373</dc:identifier>
<dc:title xml:lang="es">Riesgo cardiovascular en hemodiálisis en España: prevalencia, pautas de actuación y objetivos (estudio MAR)</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21067</dc:subject>
<dc:subject>^d755</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d23925</dc:subject>
<dc:subject>^d29407^s22020</dc:subject>
<dc:subject>^d6916^s22083</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d3343^s22080</dc:subject>
<dc:subject>^d50497</dc:subject>
<dc:subject>^d7130</dc:subject>
<dc:type>article</dc:type>
<dc:date>200505</dc:date>
</metadata>
</record>
</ibecs-document>
